We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Revelation Biosciences Inc | NASDAQ:REVB | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0622 | 3.13% | 2.0522 | 2.00 | 2.06 | 2.08 | 1.995 | 2.04 | 4,473 | 16:32:35 |
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that its Chief Executive Officer James Rolke will participate in a virtual fireside chat at the 36th Annual Roth Conference scheduled for March 17-19, 2023 to be held at The Ritz Carlton, Laguna Niguel in Dana Point, California.
Details regarding the Revelation fireside chat are as follows:
35th Annual Roth Conference Presentation Details
Date:
Monday, March 18, 2023
Time:
11:00 a.m. Pacific Time
Location:
The Ritz Carlton, Laguna Niguel, CA
Webcast:
REVB Webcast Link
A live webcast of the presentation will also be available in the Investor Relations section of Revelation’s website at https://www.revbiosciences.com. A replay of the presentation will be available on Revelation’s website for 30 days following the event.
Mr. Rolke will be available for one-on-one meetings throughout the conference in person and virtually.
About Revelation Biosciences Inc.
Revelation Biosciences, Inc. is a life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including GEMINI-SSI as a prevention for post-surgical infection, GEMINI-AKI as a prevention for acute kidney injury, and GEMINI-CKD for the treatment of chronic kidney disease.
For more information on Revelation, please visit www.RevBiosciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240312834070/en/
Sandra Vedrick Vice President, Investor Relations & Human Resources Revelation Biosciences Inc. Email: svedrick@revbiosciences.com
and
Chester Zygmont, III Chief Financial Officer Revelation Biosciences Inc. Email: czygmont@revbiosciences.com
1 Year Revelation Biosciences Chart |
1 Month Revelation Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions